Body weight loss influences prescribing decisions for type 2 diabetes
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of type 2 diabetes, surveyed endocrinologists and...
View ArticleNew research: Fluid retention may explain drugs' risk of strokes and heart...
New research shows that medications which have raised safety concerns over heart attack and stroke risks may not have gotten approval from the Food and Drug Administration if the cardiovascular effects...
View ArticleFDA approves ONGLYZA to treat type 2 diabetes patients with renal impairment
Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration has approved the inclusion of data from two clinical studies in an update to the ONGLYZA U.S....
View ArticleEuropean Commission approves BMY's ONGLYZA to treat type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved a label update for ONGLYZA in the treatment of adults with type 2 diabetes who have moderate or...
View ArticleONGLYZA used with insulin maintains improvement in glucose control in adults...
Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with...
View ArticleEuropean Commission approves ONGLYZA as combination therapy with insulin for...
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to...
View ArticleBristol-Myers Squibb to acquire Amylin
Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step...
View ArticleBristol-Myers Squibb completes acquisition of Amylin
Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial...
View ArticleEU approves Forxiga for treatment of type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union....
View ArticleBristol-Myers Squibb and AstraZeneca announce top line results of Phase 4...
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with...
View ArticleShort-term blood sugar control in diabetes patients has limited effect on...
An international study has shown that short-term blood sugar control in patients with diabetes has a limited effect on their risk of cardiovascular problems, such as heart disease and stroke.
View ArticleDPP-4 inhibitors may reduce risk of autoimmune diseases
Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research...
View ArticleBristol-Myers Squibb signs agreement to sell global diabetes business
Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement,...
View ArticleNew edition of RADAR includes review of glycopyrronium for COPD treatment
NPS MedicineWise has published a new edition of RADAR, including a review of glycopyrronium (Seebri Breezhaler), a new medicine for the treatment of chronic obstructive pulmonary disease (COPD).
View ArticleOral regimens could offer simple solution for severe hyperglycaemia
Study findings indicate that oral treatments could offer a simpler alternative to upfront insulin for patients who have severe hyperglycaemia at the time of diagnosis with Type 2 diabetes.
View ArticleEuropean Commission approves ONGLYZA as combination therapy with insulin for...
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA (saxagliptin) for use as a combination therapy with insulin (with or without metformin) to...
View ArticleBristol-Myers Squibb to acquire Amylin
Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step...
View ArticleBristol-Myers Squibb completes acquisition of Amylin
Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial...
View ArticleEU approves Forxiga for treatment of type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union....
View ArticleBristol-Myers Squibb and AstraZeneca announce top line results of Phase 4...
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with...
View Article